about
What are the health costs of uranium mining? A case study of miners in Grants, New MexicoOptimal Retirement with Increasing Longevity.Costs associated with low birth weight in a rural area of Southern Mozambique.Disparity and convergence: Chinese provincial government health expendituresLabor force participation and human capital increases in an aging population and implications for U.S. research investmentThe cost of an additional disability-free life year for older Americans: 1992-2005Technology Diffusion and Productivity Growth in Health Care.NIH funding trajectories and their correlations with US health dynamics from 1950 to 2004.Efficiency of Health Investment: Education or Intelligence?Long-term economic growth stimulus of human capital preservation in the elderly.Economic evaluations of Haemophilus influenzae type b vaccine: systematic review of the literature.Heterogeneous Costs of Alcohol and Drug Problems Across Cities and Counties in California.The effect of population aging on health expenditure growth: a critical review.Health Care Expenditure and Income: A Global Perspective.Measuring the patient health, societal and economic benefits of US pediatric therapeutics legislation.The impact of pharmaceutical innovation on premature mortality, cancer mortality, and hospitalization in Slovenia, 1997-2010.The Welfare Cost of Homicides in Brazil: Accounting for Heterogeneity in the Willingness to Pay for Mortality Reductions.The value of health.The Grossman model after 40 years: a reply to Peter Zweifel.Diminishing willingness to pay per quality-adjusted life year: valuing acute foodborne illness.Market failure in the pharmaceutical industry and how it can be overcome: the CureShare mechanism.Local and global returns from research in stem cells: the case of the California Institute for Regenerative Medicine.Examining the link between cash flow, market value, and research and development investment spending in the medical device industry.The social costs of uranium mining in the US Colorado Plateau cohort, 1960-2005.Contribution of pharmaceutical innovation to longevity growth in Germany and France, 2001-7.Dialogue at Davos for an aging world.Creating the Responsible Consumer: Moralistic Governance Regimes and Consumer Subjectivity
P2860
Q28394358-EEA7F92B-1B6D-4D3A-90F3-EE3C9398A33EQ33772691-B98C1C5A-6631-4C99-BF99-4BF58A11AC68Q34103336-7AC8EE6A-54B8-4080-A9F3-54170A24BA5AQ34971208-DD40F678-717E-4DD5-B43A-99C67DB05A81Q35843667-499C71EA-08F2-4E16-88BE-39AC01E2C989Q36661498-D21799D7-F6FC-4136-B17F-AB7F7477CBC7Q36687809-231E5C02-AA41-4160-8FD8-AA33FEB6B43EQ37237067-17CA3FE4-8771-4791-987D-10ACAD441AF5Q37338988-5C22C0AB-B16D-4906-8B09-1B9630706608Q37448249-DF884353-7CD8-4AA8-9F53-5881A13F8027Q37577895-57662F3B-18F4-4E4C-BFCF-8E753C584BDFQ38375928-929CBCA9-B659-4BE6-85AB-187C497A99E8Q38626824-641796B8-0FBF-47C0-A3EF-0F9A6D1D24BCQ39344276-A6AD9761-898F-4AA3-A51A-9BECA5A4BFE3Q39589482-3853D125-F777-4D38-A2A7-A80D5E7A1319Q41616714-2B557842-1CCF-4865-8CA5-311299D2D4B9Q41671455-C7D5DA2A-280D-457C-83DB-B239752AE410Q43025579-A35DB6D5-2851-4845-8066-54A9BFEF2A84Q45452014-1A447D93-1B50-42CF-BF81-10283EB37F92Q45907158-F7A62C2D-F8F9-4B70-9AE6-8322AF520CD4Q46013272-33A81BD3-EA1B-4B2C-956C-C9CE6059F1F5Q46035265-2ACD8E4C-C75F-4170-B17E-BDEAED01BAF2Q46320097-E990269A-AF01-43C9-97C4-93BAC25D5433Q47972381-7F0BE5E2-D83E-4A56-92AD-140635213EC8Q51177186-1391F779-ED3A-4EF4-9812-D0AD96E47253Q51685987-866A7938-8AA5-4A05-95AF-013A4BF0C6FCQ55870152-59AE8778-89C9-4532-8D46-BC4D97EACF17
P2860
description
article
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в жовтні 2006
@uk
ലേഖനം
@ml
name
The Value of Health and Longevity
@en
The Value of Health and Longevity
@nl
type
label
The Value of Health and Longevity
@en
The Value of Health and Longevity
@nl
prefLabel
The Value of Health and Longevity
@en
The Value of Health and Longevity
@nl
P356
P1476
The Value of Health and Longevity
@en
P2093
Kevin M. Murphy
Robert H. Topel
P304
P356
10.1086/508033
P577
2006-10-01T00:00:00Z